A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

To join this study, people need to have been diagnosed with multiple myeloma using standard tests. Your doctor must also confirm that your myeloma has either worsened or not responded to your most recent treatments. This includes people who have previously received specific BCMA-targeting treatments like CAR-T cell therapy or certain antibody drugs, and whose myeloma is still not responding to at least three different types of standard treatments.

You also need to be generally in good health, able to look after yourself, and not have any health problems that would make taking part unsafe. For instance, your daily activities shouldn't be significantly limited by your illness, and you should be expected to live for at least 12 more weeks. Any side effects from your previous cancer treatments should have mostly cleared up and be mild.

It's important that you haven't been pregnant or breast-feeding before or during the study, as the medication could affect an unborn baby or breastfed infant. Men and women capable of having children will need to use effective contraception during and for some time after the study. You also can't have been treated with cevostamab or a very similar medicine before, or be unable to attend hospital visits as required by the study.

If you decide to take part in this study, you will receive the study medication, cevostamab, through a drip into your vein. In some cases, a second medicine called tocilizumab might also be given. You will need to attend regular hospital visits so the medical team can monitor your health, check how you are responding to the treatment, and manage any side effects. This will involve various assessments, including blood tests. You will also need to provide bone marrow samples (a biopsy and aspirate) at specific times during the study, as outlined by the research team. The study involves regular follow-up to ensure your safety and track your progress. The total length of your participation will depend on how you respond to the treatment and the study's specific plan, but it will involve ongoing assessments as long as you are receiving the study drug and for a period afterwards.